Genome-wide DNA hypomethylation associated with DNMT3A mutation in murine and human FLT3ITD AML. Human: A–C, volcano plot (A) representation of mean methylation.

Slides:

Advertisements

Similar presentations

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of a Leukemic Stem Cell Gene Expression.

Advertisements

DNA Methylation Regulates Gene Expression in Intracranial Aneurysms

Neo-cartilage engineered from primary chondrocytes is epigenetically similar to autologous cartilage, in contrast to using mesenchymal stem cells N.

Figure 3. Active enhancers located in intergenic DMRs

Volume 14, Issue 1, Pages (January 2014)

BCR–ABL1 B-ALLs feature DNA methylation and expression signatures centered aroundIL2RA(CD25). BCR–ABL1 B-ALLs feature DNA methylation and expression signatures.

Hypomethylation Status of CpG Sites at the Promoter Region and Overexpression of the Human MDR1 Gene in Acute Myeloid Leukemias by Masaharu Nakayama, Morimasa.

Laila C. Schenkel, Charles Schwartz, Cindy Skinner, David I

Pig iPSCs are reprogrammed differently and show genome-wide hypomethylation compared with mouse and human. Pig iPSCs are reprogrammed differently and show.

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.

Volume 27, Issue 4, Pages (April 2015)

The nasal methylome and childhood atopic asthma

Neo-cartilage engineered from primary chondrocytes is epigenetically similar to autologous cartilage, in contrast to using mesenchymal stem cells N.

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features by Maria E. Figueroa, Bas J.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Volume 61, Issue 6, Pages (June 2012)

by Gregory H. Underhill, David George, Eric G. Bremer, and Geoffrey S

Shiran Bar, Maya Schachter, Talia Eldar-Geva, Nissim Benvenisty

Volume 9, Issue 3, Pages (September 2017)

Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia by Floriana Manodoro, Jacek Marzec, Tracy.

by Kentson Lam, Alexander Muselman, Randal Du, Yuka Harada, Amanda G

Volume 25, Issue 4, Pages (April 2014)

Volume 33, Issue 4, Pages e6 (April 2018)

Reversing the TERT promoter mutation to WT reverses the active chromatin marks and alters long-range chromatin interactions. Reversing the TERT promoter.

Volume 22, Issue 3, Pages (January 2018)

Figure 2. Ectopic expression of PLZF modulates H3K27ac at enhancer regions in myeloid cells. (A) Box plots showing ... Figure 2. Ectopic expression of.

Volume 63, Issue 4, Pages (August 2016)

Volume 22, Issue 3, Pages (January 2018)

Volume 12, Issue 4, Pages (April 2013)

Bar plot representation of the transcriptomic changes in Δsaci_ptp and Δsaci_pp2a. Bar plot representation of the transcriptomic changes in Δsaci_ptp and.

Gene expression changes upon modulation of DNMT3A transcripts.

Shiran Bar, Maya Schachter, Talia Eldar-Geva, Nissim Benvenisty

Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo

Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo

Volume 30, Issue 1, Pages (July 2016)

A rapid, spontaneous, and fully penetrant model of cytogenetically normal AML utilizing Flt3ITD and Dnmt3a haploinsufficiency. A rapid, spontaneous, and.

DNMT3A variants cause unique DNAm signatures.

Volume 1, Issue 1, Pages (June 2013)

Volume 29, Issue 5, Pages (May 2016)

Volume 12, Issue 12, Pages (September 2015)

Polycomb Responds to Low Levels of Transcription

Significant differences in translational efficiencies of DNA damage repair pathway genes between patient clusters. Significant differences in translational.

James M. Flanagan, Sibylle Cocciardi, Nic Waddell, Cameron N

Differential binding of H3K36me3 in G34-mutant KNS42 cells drives pediatric GBM expression signatures. Differential binding of H3K36me3 in G34-mutant KNS42.

DNMT3A1 signatures are not recapitulated in AML.

DNMT3A2 signatures are coherently modified in AML.

Volume 12, Issue 8, Pages (August 2015)

Analysis of renal transcriptome responses identifies LX-regulated transcriptional networks. Analysis of renal transcriptome responses identifies LX-regulated.

Reanalysis of an existing experiment using ADAGE

Epigenome-wide differential methylation in RUL macrophages.

Visual display of the proportions of hyper- and hypomethylated differentially methylated targets (DMT) relative to reference muscularis tissue in SDH-

Loss of BAP1 blocks T cell differentiation at the DN3 stage in vitro.

Overexpression of IL-27 upregulates expression of multiple IR by T cells in vivo. Overexpression of IL-27 upregulates expression of multiple IR by T cells.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

EZH2 overexpression establishes a unique and conserved super-enhancer–associated transcriptional landscape. EZH2 overexpression establishes a unique and.

Leukemic blasts express a “hypoxia signature

Integrated mRNA and microRNA expression and DNA methylation clusters.

JAK2V617F leads to increased 5-hmC and genome-wide loss of cytosine methylation in primary patient samples. JAK2V617F leads to increased 5-hmC and genome-wide.

Response of the Idh2R140Q Flt3ITD leukemia model to AG-221 therapy.

Heat map of genes for which CR significantly altered expression versus AL. Cluster analysis of genes significantly changed by the CR intervention compared.

Transcriptional and genomic targets of EN1 in TNBC cells.

Specific DNA methylation and expression signatures associated with binding of E2A–PBX1 fusion protein. Specific DNA methylation and expression signatures.

SY-1425 shows similar response in RARA-high AML cell lines to APL

CREBBP loss-of-function results in gene expression repression signature. CREBBP loss-of-function results in gene expression repression signature. A–D,

Response of Tet2−/− Flt3ITD leukemia model to 5-Aza therapy.

A, Epigenetic validation results of CBFA2T3 and GABBR2, which were first screened by MSCC sequencing and further confirmed by a Sequenom EpiTYPER assay.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

EZH2-driven lung cancer as a molecularly distinct entity.

The Transcription and H3K4me3 Methylation Levels of Many SAGs Are Upregulated in jmj16-1. The Transcription and H3K4me3 Methylation Levels of Many SAGs.

Integrated analysis of gene expression and copy number alterations.

Presentation transcript:

Genome-wide DNA hypomethylation associated with DNMT3A mutation in murine and human FLT3ITD AML. Human: A–C, volcano plot (A) representation of mean methylation difference (x-axis) versus statistical significance (y-axis). Genome-wide DNA hypomethylation associated with DNMT3A mutation in murine and human FLT3ITD AML. Human: A–C, volcano plot (A) representation of mean methylation difference (x-axis) versus statistical significance (y-axis). Red dots designate significantly hypo- and hypermethylated regions in patients with FLT3ITD/DNMT3A-mutant AML compared to patients with FLT3ITD alone. B, heatmap representation of DMRs in FLT3ITD/DNMT3A-mutant AML compared to FLT3ITD/DNMT3AWT AML. Corresponding methylation levels are also shown in normal human bone marrow HSCs for normal baseline comparison. C, proportion of all measured CpGs by ERRBS (all tiles) and differentially methylated in FLT3ITD/DNMT3A-mutant versus FLT3ITD/DNMT3AWT AML (DMRs, hypermethylated, and hypomethylated) in genomic, CpG island (CpGi), and enhancer regions. Murine (n = 3 mice/group): D–F, volcano plot (D) representation of mean methylation difference (x-axis) versus statistical significance (y-axis). Red dots designate significantly DMRs in Flt3ITD/ITD;Dnmt3afl/flMxCre AML compared to Flt3ITD/ITD;Dnmt3afl/fl MPN. E, heatmap representation of DMRs in Flt3ITD/ITD;Dnmt3afl/flMxCre AML compared to Flt3ITD/ITD;Dnmt3afl/fl MPN. Corresponding methylation levels are also shown in WT murine LIN−SCA-1+c-KIT+ (LSK) as a normal baseline comparison. HSPC-like genes share similar methylation patterns with WT LSK (indicated by gray sidebars), and AML-unique regions are differentially methylated from both MPN and WT LSK (indicated by gold sidebars). F, proportion of differentially methylated genomic, CpGi, and enhancer regions in all measured CpGs (all tiles) and DMRs (hypermethylated and hypomethylated) in Flt3ITD/ITD;Dnmt3afl/flMxCre AML compared to Flt3ITD/ITD;Dnmt3afl/fl MPN murine models. G, gene expression: hierarchical clustering of significantly differentially expressed genes in Flt3ITD/ITD;Dnmt3afl/flMxCre AML compared to Flt3ITD/ITD;Dnmt3afl/fl MPN. Gene expression is also shown for WT LSK, common myeloid progenitors (CMP), and granulocyte–monocyte progenitors (GMP) murine bone marrow cells as normal baseline comparison. “HSPC-like” genes are expressed in AML and LSK but not in CMP, GMP, or MPN. “AML-unique” genes are differentially expressed in AML compared to all other samples. H, GSEA: genes upregulated in murine AML versus MPN were ranked according to descending gene expression in human FLT3ITD/DNMT3A-mutant AML versus FLT3ITD/DNMT3AWT AML. I, dot plot representation of mean methylation difference for all differentially methylated genes in c-KIT+Flt3ITD/ITD;Dnmt3afl/flMxCre AML compared to Flt3ITD/ITD;Dnmt3afl/fl MPN (x-axis), versus their corresponding gene expression fold change (y-axis) (n = 3 mice/group). Genes whose gene expression changes overlapped with changes in methylation are highlighted in red. J, GSEA: genes corresponding to hypomethylated regions in murine Flt3ITD/ITD;Dnmt3afl/flMxCre AML (compared to MPN) were ranked according to descending gene expression in murine AML versus MPN. K, RT-qPCR validation of representative genes from AML-unique and HSPC-like groups in G that were hypomethylated in murine c-KIT+ splenocytes from Flt3ITD/ITD;Dnmt3afl/flMxCre AML (red boxes) versus Flt3ITD/ITD;Dnmt3afl/fl MPN (blue boxes) (n = 5 mice/group). Statistical significance was evaluated for each gene by unpaired parametric t test compared to Flt3ITD/ITD;Dnmt3afl/fl control. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. Sara E. Meyer et al. Cancer Discov 2016;6:501-515 ©2016 by American Association for Cancer Research